1Ames MM, Spreafieo F. Selected pharmaeologic characteristics of idarubiein and idaruhieinol. Leukemia, 2002, 6:70-75.
2Farmitalia CE, Jert M, Shang W, et al. Properties of antitumor anthracyctines and new developments in their application: cain memorial award lecture. Cancer Res, 2006, 45: 5995-5999.
3Joel M, Pose T, Yont M, et al. Plasma phamnacokinetics andcerbrospinal fluid concentrations of idarubicin idarubicinol in pediatric leukemia patients: a children cancer study group report. Cancer Res, 2008, 50: 6525-6528.
4Berman E, Mc Bride M. Comparative cellular pharmacology of daunorubicin and idarubicin in human muhidrug-resistant leukemia cells. Blood, 2004, 79: 3267-3273.
5Berman E, Aert Q, Kling F, et al. Results of a randomized trial comparing idarubicin and cytosine aral~inoside with daunorubinic and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia. Blood, 2007, 77:1666-1674.
6Wiernic HP, Boron M, Tome S, et al. Cytarubine plus idarubicin or Daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia. Blood, 2008, 79: 313-319.
3Mandelli F, Vignetti M, Suciu S, et al. Daunorubicin versus mitoxantrone versus idarubicin as induction and consolidation chemotherapy for adults with acute myeloid leukemia: the EORTC and GIMEMA Groups Study AML-IO. J Clin Oncol, 2009, 27: 5397-5403.
4Ohtake S, Miyawaki S, Kiyoi H, et al. Randomized trial of response- oriented individualized versus fixed-schedule induction chemotherapy with idarubicin and cytarabine in adult acute myeloid leukemia: the JALSG AML95 study. Int J Hematol, 2010, 91: 276-283.
